Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes.
Leuk Res
; 36(11): 1434-7, 2012 Nov.
Article
em En
| MEDLINE
| ID: mdl-22874537
ABSTRACT
The PRH/Hhex transcription factor represses multiple genes in the VEGF signalling pathway (VSP) to inhibit myeloid cell survival. Protein kinase CK2 phosphorylates PRH and counteracts the inhibitory effect of this protein on cell survival by blocking the repression of VSP genes. Here we show that the BCR-ABL/Src kinase inhibitor dasatinib decreases PRH phosphorylation and increases PRH-dependent repression of Vegf and Vegfr-1. Moreover in the absence of PRH, dasatinib does not inhibit cell survival as effectively as in PRH expressing cells. Thus the re-establishment of gene control by PRH is in part responsible for the therapeutic effects of dasatinib.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Tiazóis
/
Fatores de Transcrição
/
Transdução de Sinais
/
Leucemia
/
Regulação Neoplásica da Expressão Gênica
/
Proteínas de Homeodomínio
/
Fator A de Crescimento do Endotélio Vascular
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article